Drug Profile

Reasearch programme: renal disorders therapeutics - Foventa Therapeutics

Alternative Names: mRNA targeted therapies; mRNA targeted therapies- Foventa Therapeutics

Latest Information Update: 03 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exonate
Developer Foventa Therapeutics
Class Small molecules
Mechanism of Action Cyclin-dependent kinase-activating kinase modulators; RNA splicing modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Sep 2026 Exonate is now called Foventa Therapeutics
21 Apr 2023 Early research in Diabetic nephropathies in United Kingdom (unspecified route) (Exonate pipeline, April 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com